Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

376

HTML

2478

Tables (1-1)

181

Sum=3035

Nov 28, 2012 (publication date) through Nov 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Field Of Vision

World J Gastroenterol. Nov 28, 2012; 18(44): 6376-6378
Published online Nov 28, 2012. doi: 10.3748/wjg.v18.i44.6376

Table 1 Clinical decision tool for second-line therapy

Prognostic marker	Treatment action
Prognostic marker	Support treatment	Caution-poor outcome
Albumin (mg/dL)	> 35	< 35
Performance status	0-1	2
Chemotherapy free interval (mo)	> 3	< 3
Time to progression on 1st-line therapy (mo)	> 6	< 6

Citation: Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? World J Gastroenterol 2012; 18(44): 6376-6378
URL: https://www.wjgnet.com/1007-9327/full/v18/i44/6376.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i44.6376